LASR? Platform
Therapeutic Areas
Long-Acting and Sustained-Release Peptide Platform
1. Next generation of peptide half-life extension technology renders drugs to be in a ready-to-use liquid form and dosed once-monthly or
even lower frequency to maximally increase dosing conveniece and patient compliance.
2. Patented sustained-release technology allows precisely controlled release of peptide of high activities with minimal plasma peak and
trough ratio to mitigate high Cmax driven safety risks.